ACC.24 - Akshay Desai shares the findings of the phase 2 KARDIA-2 trial. “Treatment with zilebesiran seems to be an effective therapy to incrementally reduce blood pressure in patients with mild-to-moderate hypertension despite treatment with indapamide, amlodipine or olmesartan”, says Akshay Desai.
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Restart
Resume
Transcript
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Akshay Suvas Desai, MD is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital, Boston, MA, US. In addition, he is an associate professor of medicine at Harvard Medical School, Boston, MA, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 17 april 2024
Recommended
Details
Presenters
Overview
ACC.24 - Akshay Desai shares the findings of the phase 2 KARDIA-2 trial. “Treatment with zilebesiran seems to be an effective therapy to incrementally reduce blood pressure in patients with mild-to-moderate hypertension despite treatment with indapamide, amlodipine or olmesartan”, says Akshay Desai.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Akshay Suvas Desai, MD is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital, Boston, MA, US. In addition, he is an associate professor of medicine at Harvard Medical School, Boston, MA, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 17 april 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
1.00 credits
<p>Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
1.00 credits
<p>Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D</p>
MinuteCE®
Clinical Conundrums in ARIA: How to Manage Asymptomatic ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: How to Manage Asymptomatic ARIA</p>
CME/CE Broadcast Replay
Pulmonary Hypertension Management: Practice Trends and Updates
1.00 credits
<p>Pulmonary Hypertension Management: Practice Trends and Updates</p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
NeuroFrontiers
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms
<p>Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms</p>
Clinician's Roundtable
Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder
<p>Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?